Alirocumab vs Evolocumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals and partners
NCT01507831 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Reported efficacy
DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)
Result source: NCT03510884
Evolocumab · Repatha
Marketed by Amgen
NCT01516879 · Phase 3 · completed
The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.
Next expected readout: November 2026 · NCT06496243 (registry estimate)
Reported efficacy
Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)
Result source: NCT02392559
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alirocumab | Evolocumab |
|---|---|---|
| LDL-C, % change | -52.7% vs -0.3%−52.4 vs placeboNCT01926782165 other results
| -50.1% vs 6.8%−57 vs placeboNCT0151687957 other results
|
| Non-HDL-C, % change | -51.6% vs 0.7%−52.3 vs placeboNCT0150783187 other results
| -41.8% vs 8.4%−50.3 vs placeboNCT0151687950 other results
|
| ApoB, % change | -52.8% vs 1.2%−54 vs placeboNCT0150783186 other results
| -41.3% vs 2.9%−44.2 vs placeboNCT0151687953 other results
|
| Lp(a), % change | -29.3% vs -3.7%−25.6 vs placeboNCT0150783164 other results
| -16.4% vs 10.3%−26.8 vs placeboNCT0283384452 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04790513 | 7.9% vs 9.9%−2 vs placeboNCT017646335 other results
|
LDL-C, % change
- Alirocumab
- -52.7% vs -0.3%−52.4 vs placeboNCT01926782
165 other results
- -58.8% vs -0.1% NCT01926782
- -45.7% vs -6.6% NCT01617655
- -48.2% vs -2.3% NCT01644175
- -48.8% vs 9.1% NCT01623115
- -48.7% vs 2.8% NCT01709500
- -48.2% vs 0.8% NCT02585778
- -51.7% vs 4.7% NCT02023879
- -26.9% vs 8.6% NCT03156621
- -43.8% vs -4.3% NCT02584504
- -70.1% vs -4.3% NCT02584504
- -50.2% vs -0.3% NCT01926782
- -51.6% vs -0.1% NCT01926782
- -51.8% vs 0.8% NCT02585778
- -57.1% vs 6.3% NCT02289963
- -62.5% vs 1.6% NCT02107898
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -50.6% vs -20.7% NCT01644188
- -56% vs -20.3% NCT02715726
- -47.2% vs -15.6% NCT01644474
- -45% vs -14.6% NCT01709513
- -50.6% vs -15.9% NCT01730053
- -36.3% vs -15.9% NCT01730053
- -44.1% vs -5% NCT01730040
- -54% vs -5% NCT01730040
- -45.7% vs 8% NCT01663402
- -52.8% vs 8.2% NCT01663402
- -55.8% vs 4.4% NCT01663402
- -58.3% vs 4.4% NCT01663402
- -23.5% vs 16.4% NCT01663402
- -40.1% vs 14.6% NCT01663402
- -56.8% vs 4.4% NCT01507831
- -59.9% vs 4.6% NCT01507831
- -52.4% vs 3.6% NCT01507831
- -58% vs 3.9% NCT01507831
- -61% vs 0.8% NCT01507831
- -62.8% vs 0.7% NCT01507831
- -57.8% vs 3.5% NCT01507831
- -63.3% vs 1.5% NCT01507831
- -64.2% vs 1.4% NCT01507831
- -59.4% vs -0.4% NCT01926782
- -62.3% vs -0.3% NCT01926782
- -58.4% vs 0.3% NCT01926782
- -55.3% vs 1.1% NCT01926782
- -60% vs -0.5% NCT01926782
- -58% vs 1.4% NCT01926782
- -47.1% vs 9% NCT01623115
- -48.1% vs 9.1% NCT01623115
- -50.3% vs 8.4% NCT01709500
- -40.3% vs 11.5% NCT01623115
- -43.5% vs 5.7% NCT01623115
- -43.9% vs 5.7% NCT01623115
- -42.1% vs -3% NCT01617655
- -42% vs -2.9% NCT01617655
- -42.5% vs 0.5% NCT01644175
- -40.9% vs -0.2% NCT01617655
- -45.5% vs -6.6% NCT01617655
- -50.7% vs -0.8% NCT01644175
- -46.9% vs -6.6% NCT01617655
- -46.9% vs -6.6% NCT01617655
- -46.3% vs 1.1% NCT01644175
- -47.6% vs 1.7% NCT01644175
- -54.6% vs 5.1% NCT02023879
- -43.4% vs -2.8% NCT02584504
- -70.1% vs -2.8% NCT02584504
- -54.2% vs -3.7% NCT02584504
- -69.9% vs -3.7% NCT02584504
- -54% vs -2.6% NCT02584504
- -69.9% vs -2.6% NCT02584504
- -41.7% vs 3.2% NCT02023879
- -44.8% vs 3.6% NCT02023879
- -52.3% vs 3.2% NCT02023879
- -55% vs 3.6% NCT02023879
- -62.5% vs -3.6% NCT02107898
- -64.6% vs -3.4% NCT02107898
- -43.7% vs 14% NCT01623115
- -49.3% vs 8.8% NCT01623115
- -49.4% vs 2.7% NCT01709500
- -55.3% vs 5.1% NCT02023879
- -50.9% vs 0.7% NCT02585778
- -43.3% vs 2.4% NCT02585778
- -63.7% vs 1.7% NCT02107898
- -43.8% vs 4.6% NCT01709500
- -44.2% vs 4.6% NCT01709500
- -48.8% vs 1.4% NCT02585778
- -44.8% vs -0.8% NCT02585778
- -42.3% vs 4% NCT02326220
- -26.9% vs 8.6% NCT03156621
- -53.7% vs 1.6% NCT02326220
- -54.6% vs -0.4% NCT01926782
- -55.1% vs -0.3% NCT01926782
- -53.8% vs 0.7% NCT02585778
- -64.2% vs -2.7% NCT02107898
- -49.4% vs 2.4% NCT02585778
- -60.2% vs 6% NCT02289963
- -51.8% vs 0.3% NCT01926782
- -45.3% vs 1.1% NCT01926782
- -53.9% vs -0.5% NCT01926782
- -47.3% vs 1.4% NCT01926782
- -50.8% vs 3.2% NCT02023879
- -51.5% vs 3.6% NCT02023879
- -49.4% vs 1.4% NCT02585778
- -46.7% vs -0.8% NCT02585778
- -57.9% vs 4.7% NCT02289963
- -58.4% vs 4.7% NCT02289963
- -64.8% vs -2.8% NCT02107898
- -53.6% vs 3.2% NCT02023879
- -54.1% vs 3.6% NCT02023879
- -37.9% vs 1.2% NCT01617655
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -49.5% vs -18.3% NCT01644188
- -51.8% vs -19.7% NCT01644188
- -52.4% vs -21.8% NCT01644188
- -51.2% vs -21.8% NCT01644188
- -52.4% vs -22.7% NCT01644188
- -44.2% vs -15.2% NCT01644188
- -48.9% vs -17% NCT01644188
- -58.7% vs -21.3% NCT02715726
- -57.1% vs -22.2% NCT02715726
- -58.1% vs -22.7% NCT02715726
- -48.1% vs -19.6% NCT01644474
- -52.2% vs -17.1% NCT01709513
- -47.3% vs -15.2% NCT01709513
- -47% vs -15.6% NCT01709513
- -51.2% vs -18% NCT01709513
- -53.5% vs -17% NCT01730053
- -41.5% vs -17% NCT01730053
- -48.6% vs -6.1% NCT01730040
- -57.8% vs -6.1% NCT01730040
- -49.6% vs -22.1% NCT01730053
- -32.3% vs -22.1% NCT01730053
- -52.6% vs -22.9% NCT01730053
- -35.1% vs -22.9% NCT01730053
- -48.4% vs -8.5% NCT01730040
- -50.5% vs -8.5% NCT01730040
- -53.7% vs -9.2% NCT01730040
- -50.9% vs -9.2% NCT01730040
- -66.2% vs -51.2% NCT03415178
- -73% vs 2% NCT02938949
- -51.4% vs 2.8% NCT02957682
- -50.4% vs 2.4% NCT02957682
- -54.2% vs 3% NCT02957682
- -49.6% vs 0.6% NCT02957682
- -46.2% vs 4% NCT02957682
- -43.3% vs -0.3% NCT02642159
- -41.7% vs -7% NCT02642159
- -63.9% vs -13.4% NCT02984982
- -64.5% vs -7.6% NCT02984982
- Evolocumab
- -50.1% vs 6.8%−57 vs placeboNCT01516879
57 other results
- -44.5% vs -6.2% NCT02392559
- -55.2% vs 1.7% NCT02833844
- -61.6% vs 8.1% NCT01763866
- -58.2% vs 8.1% NCT01763866
- -61.8% vs 8.1% NCT01763866
- -58.7% vs 8.1% NCT01763866
- -60.1% vs 8.1% NCT01763866
- -59.4% vs 8.1% NCT01763866
- -58.9% vs 8.1% NCT01763866
- -52.4% vs 8.1% NCT01763866
- -65.9% vs 8.1% NCT01763866
- -57.0% vs 8.1% NCT01763866
- -57.0% vs -1.3% NCT01763827
- -56.1% vs -1.3% NCT01763827
- -62.3% vs 7.1% NCT02662569
- -54.3% vs -1.1% NCT02739984
- -69.0% vs 4.9% NCT02662569
- -61.3% vs 5.5% NCT01763918
- -55.7% vs 5.5% NCT01763918
- -64.7% vs 7.1% NCT02662569
- -73.6% vs 1.4% NCT01953328
- -64.6% vs 1.4% NCT01953328
- -74.5% vs 1.4% NCT01953328
- -70.4% vs 1.4% NCT01953328
- -73.7% vs -0.4% NCT01953328
- -70.0% vs -0.4% NCT01953328
- -74.8% vs -0.4% NCT01953328
- -76.9% vs -0.4% NCT01953328
- -61.4% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -61.8% vs 7.5% NCT01763866
- -65.0% vs 7.5% NCT01763866
- -59.3% vs 7.5% NCT01763866
- -63.8% vs 7.5% NCT01763866
- -59.1% vs 7.5% NCT01763866
- -62.9% vs 7.5% NCT01763866
- -66.2% vs 7.5% NCT01763866
- -62.5% vs 7.5% NCT01763866
- -56.9% vs -1.4% NCT01763827
- -58.8% vs -1.4% NCT01763827
- -61.2% vs 2.3% NCT01763918
- -63.3% vs 2.3% NCT01763918
- -65.3% vs 4.9% NCT02662569
- -65.0% vs -0.8% NCT02739984
- -23.1% vs 7.9% NCT01588496
- -52.8% vs -16.7% NCT01984424
- -56.1% vs -18.1% NCT01763905
- -52.6% vs -18.1% NCT01763905
- -54.5% vs -16.7% NCT01984424
- -56.1% vs -19.2% NCT01763905
- -55.3% vs -19.2% NCT01763905
- -54.4% vs 3.2% NCT01516879
- -59.0% vs 1.6% NCT02729025
- -48.0% vs -5.9% NCT02392559
- -57.8% vs -0.7% NCT02189837
- -83.2% vs -0.7% NCT02189837
- -25.6% vs 4.2% NCT01588496
Non-HDL-C, % change
- Alirocumab
- -51.6% vs 0.7%−52.3 vs placeboNCT01507831
87 other results
- -53.1% vs 0.6% NCT01507831
- -53.7% vs 0.9% NCT01507831
- -43.3% vs -0.3% NCT01926782
- -49.7% vs 0.3% NCT01926782
- -48.9% vs 0.1% NCT01926782
- -52.6% vs 0.2% NCT01926782
- -49.9% vs -0.4% NCT01926782
- -46.5% vs 0.6% NCT01926782
- -42.8% vs 9.6% NCT01623115
- -43.3% vs 9.4% NCT01623115
- -38.4% vs 5.3% NCT01623115
- -41.9% vs -6.2% NCT01617655
- -41.7% vs -6.1% NCT01617655
- -39.1% vs -1.6% NCT01644175
- -40.9% vs -0.5% NCT01644175
- -41.4% vs -6.9% NCT01617655
- -37.4% vs 2.6% NCT01644175
- -42.6% vs 3.1% NCT01709500
- -43.2% vs 3.1% NCT01709500
- -37.9% vs 0.7% NCT02585778
- -44.2% vs 4.8% NCT02023879
- -46.7% vs 5% NCT02023879
- -36.2% vs -4.9% NCT02584504
- -61.1% vs -4.9% NCT02584504
- -35.9% vs -3.5% NCT02584504
- -61.1% vs -3.5% NCT02584504
- -34.9% vs 3% NCT02023879
- -45.3% vs 4.8% NCT02023879
- -46.9% vs 5% NCT02023879
- -45.9% vs 0.7% NCT02585778
- -47.2% vs 4.3% NCT02289963
- -50.1% vs 4.1% NCT02289963
- -54.9% vs 2.6% NCT02107898
- -56% vs 2.6% NCT02107898
- -43.4% vs 3% NCT02023879
- -47.3% vs 3.9% NCT02289963
- -56.3% vs -1.7% NCT02107898
- -35.7% vs 4.7% NCT02326220
- -24.8% vs 8% NCT03156621
- -24.8% vs 8% NCT03156621
- -47.1% vs 2.8% NCT02326220
- -41.6% vs 0.3% NCT01926782
- -37.9% vs 4.1% NCT01709500
- -43.6% vs -0.3% NCT01926782
- -47.2% vs 0.1% NCT01926782
- -44.4% vs 0.2% NCT01926782
- -45.8% vs -0.4% NCT01926782
- -37.4% vs 0.6% NCT01926782
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -42.1% vs -19.2% NCT01644188
- -43.7% vs -20.2% NCT01644188
- -42.6% vs -20.6% NCT01644188
- -47% vs -19.4% NCT02715726
- -49.1% vs -20.4% NCT02715726
- -47.4% vs -20.7% NCT02715726
- -40.6% vs -15.1% NCT01644474
- -42.5% vs -16.7% NCT01644474
- -40.2% vs -14.6% NCT01709513
- -46.9% vs -17.1% NCT01709513
- -41.5% vs -15.8% NCT01709513
- -42.7% vs -11.2% NCT01730053
- -31.4% vs -11.2% NCT01730053
- -45.7% vs -14.9% NCT01730053
- -35.6% vs -14.9% NCT01730053
- -36.7% vs -6.3% NCT01730040
- -47.6% vs -6.3% NCT01730040
- -40.5% vs -7.5% NCT01730040
- -50.5% vs -7.5% NCT01730040
- -41.2% vs -18% NCT01730053
- -29.8% vs -18% NCT01730053
- -40.6% vs -7.1% NCT01730040
- -42.3% vs -7.1% NCT01730040
- -37.3% vs -4.7% NCT02642159
- -44% vs 2.2% NCT02957682
- -40.4% vs 0.7% NCT02957682
- -41.1% vs 1.7% NCT02957682
- -40.6% vs 1.7% NCT02957682
- -37% vs 2.5% NCT02957682
- -35.5% vs -9.4% NCT02642159
- -54.5% vs -14.1% NCT02984982
- Evolocumab
- -41.8% vs 8.4%−50.3 vs placeboNCT01516879
50 other results
- -41.2% vs -6.1% NCT02392559
- -48.1% vs 2.9% NCT02833844
- -53.4% vs 7.9% NCT01763866
- -52.2% vs 7.9% NCT01763866
- -54.8% vs 7.9% NCT01763866
- -50.0% vs 7.9% NCT01763866
- -52.0% vs 7.9% NCT01763866
- -51.6% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -46.4% vs 7.9% NCT01763866
- -59.0% vs 7.9% NCT01763866
- -51.0% vs 7.9% NCT01763866
- -50.1% vs 1.5% NCT01763827
- -49.7% vs 1.5% NCT01763827
- -52.9% vs 5.9% NCT02662569
- -59.1% vs 4.3% NCT02662569
- -56.2% vs 5.3% NCT01763918
- -49.7% vs 5.3% NCT01763918
- -55.8% vs 5.9% NCT02662569
- -46.9% vs -0.6% NCT02739984
- -67.8% vs -0.1% NCT01953328
- -58.0% vs -0.1% NCT01953328
- -68.9% vs -0.1% NCT01953328
- -63.3% vs -0.1% NCT01953328
- -68.5% vs -1.6% NCT01953328
- -61.7% vs -1.6% NCT01953328
- -69.7% vs -1.6% NCT01953328
- -69.1% vs -1.6% NCT01953328
- -53.5% vs 7.0% NCT01763866
- -56.1% vs 7.0% NCT01763866
- -54.4% vs 7.0% NCT01763866
- -56.3% vs 7.0% NCT01763866
- -52.6% vs 7.0% NCT01763866
- -55.5% vs 7.0% NCT01763866
- -52.1% vs 7.0% NCT01763866
- -55.7% vs 7.0% NCT01763866
- -59.3% vs 7.0% NCT01763866
- -56.0% vs 7.0% NCT01763866
- -50.2% vs 1.3% NCT01763827
- -52.0% vs 1.3% NCT01763827
- -55.8% vs 2.7% NCT01763918
- -57.3% vs 2.7% NCT01763918
- -56.6% vs 4.3% NCT02662569
- -56.6% vs -0.1% NCT02739984
- -45.7% vs -14.6% NCT01984424
- -48.6% vs -16.5% NCT01763905
- -46.1% vs -16.5% NCT01763905
- -47.4% vs -14.4% NCT01984424
- -48.7% vs -17.2% NCT01763905
- -49.1% vs -17.2% NCT01763905
ApoB, % change
- Alirocumab
- -52.8% vs 1.2%−54 vs placeboNCT01507831
86 other results
- -54.3% vs 1.2% NCT01507831
- -55.5% vs 0.5% NCT01507831
- -40.2% vs -0.7% NCT01926782
- -45.1% vs 3.1% NCT01926782
- -44.8% vs -0.3% NCT01926782
- -47.2% vs 3.1% NCT01926782
- -46.4% vs -2.3% NCT01926782
- -41.2% vs 3.6% NCT01926782
- -41.1% vs 4.7% NCT01623115
- -41.4% vs 4.5% NCT01623115
- -34.5% vs 3.1% NCT01623115
- -39% vs -8.7% NCT01617655
- -38.9% vs -8.7% NCT01617655
- -36.7% vs -0.9% NCT01644175
- -37.9% vs -0.4% NCT01644175
- -39.2% vs -9% NCT01617655
- -34.8% vs 3.4% NCT01644175
- -42.8% vs -3.5% NCT01709500
- -43.2% vs -3.5% NCT01709500
- -33.4% vs 3.3% NCT02585778
- -38.9% vs 7.5% NCT02023879
- -40.9% vs 7.7% NCT02023879
- -32.2% vs -6% NCT02584504
- -57.9% vs -6% NCT02584504
- -31.8% vs -4.6% NCT02584504
- -58% vs -4.6% NCT02584504
- -31.3% vs 7% NCT02023879
- -39.7% vs 7.5% NCT02023879
- -41.2% vs 7.7% NCT02023879
- -39.4% vs 3.3% NCT02585778
- -42.3% vs 4.1% NCT02289963
- -45.4% vs 3.8% NCT02289963
- -55% vs -1.6% NCT02107898
- -55.9% vs -2.1% NCT02107898
- -38.4% vs 7% NCT02023879
- -40.9% vs 5.2% NCT02289963
- -54.6% vs -3.3% NCT02107898
- -33.8% vs 1.7% NCT02326220
- -22.5% vs 7.2% NCT03156621
- -22.5% vs 7.2% NCT03156621
- -42.8% vs 1.2% NCT02326220
- -36.7% vs 3.1% NCT01926782
- -35.4% vs -0.9% NCT01709500
- -39% vs -0.7% NCT01926782
- -42% vs -0.3% NCT01926782
- -38.3% vs 3.1% NCT01926782
- -40.8% vs -2.3% NCT01926782
- -33% vs 3.6% NCT01926782
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -40.7% vs -18.3% NCT01644188
- -42.1% vs -19.1% NCT01644188
- -39.7% vs -17.2% NCT01644188
- -43.5% vs -16.2% NCT02715726
- -45.2% vs -17.4% NCT02715726
- -43% vs -16.5% NCT02715726
- -36.7% vs -11% NCT01644474
- -37.3% vs -11.7% NCT01644474
- -36.3% vs -11.2% NCT01709513
- -42.6% vs -14.4% NCT01709513
- -36.1% vs -11.6% NCT01709513
- -36.5% vs -9.8% NCT01730053
- -28.3% vs -9.8% NCT01730053
- -39.5% vs -12.7% NCT01730053
- -30.4% vs -12.7% NCT01730053
- -33.7% vs -4.4% NCT01730040
- -41.9% vs -4.4% NCT01730040
- -37.7% vs -5.1% NCT01730040
- -42.7% vs -5.1% NCT01730040
- -36.1% vs -13.7% NCT01730053
- -29% vs -13.7% NCT01730053
- -38.4% vs -6.9% NCT01730040
- -36.2% vs -6.9% NCT01730040
- -40.9% vs 2.1% NCT02957682
- -36.7% vs 0.8% NCT02957682
- -39% vs 1.1% NCT02957682
- -39.1% vs 0.2% NCT02957682
- -36.4% vs 1.4% NCT02957682
- -33.8% vs -1.6% NCT02642159
- -55.1% vs -16.6% NCT02984982
- Evolocumab
- -41.3% vs 2.9%−44.2 vs placeboNCT01516879
53 other results
- -34.9% vs -2.4% NCT02392559
- -45.1% vs 2.6% NCT02833844
- -48.3% vs 3.3% NCT02729025
- -50.9% vs 6.3% NCT01763866
- -47.1% vs 6.3% NCT01763866
- -49.8% vs 6.3% NCT01763866
- -46.5% vs 6.3% NCT01763866
- -50.1% vs 6.3% NCT01763866
- -48.6% vs 6.3% NCT01763866
- -45.6% vs 6.3% NCT01763866
- -43.7% vs 6.3% NCT01763866
- -56.0% vs 6.3% NCT01763866
- -49.2% vs 6.3% NCT01763866
- -47.2% vs 1.8% NCT01763827
- -46.6% vs 1.8% NCT01763827
- -49.7% vs 3.2% NCT02662569
- -56.4% vs 2.0% NCT02662569
- -49.8% vs 4.6% NCT01763918
- -44.8% vs 4.6% NCT01763918
- -53.9% vs 3.2% NCT02662569
- -40.3% vs 1.8% NCT02739984
- -64.8% vs -2.5% NCT01953328
- -54.8% vs -2.5% NCT01953328
- -62.8% vs -2.5% NCT01953328
- -64.4% vs -4.3% NCT01953328
- -51.0% vs 5.1% NCT01763866
- -51.4% vs 5.1% NCT01763866
- -49.1% vs 5.1% NCT01763866
- -53.3% vs 5.1% NCT01763866
- -49.8% vs 5.1% NCT01763866
- -53.6% vs 5.1% NCT01763866
- -47.1% vs 5.1% NCT01763866
- -53.0% vs 5.1% NCT01763866
- -55.6% vs 5.1% NCT01763866
- -54.4% vs 5.1% NCT01763866
- -47.0% vs 1.5% NCT01763827
- -49.4% vs 1.5% NCT01763827
- -49.6% vs 2.2% NCT01763918
- -52.8% vs 2.2% NCT01763918
- -55.0% vs 2.0% NCT02662569
- -50.2% vs 2.3% NCT02739984
- -19.2% vs 4.0% NCT01588496
- -58.0% vs -2.5% NCT01953328
- -64.8% vs -4.3% NCT01953328
- -58.5% vs -4.3% NCT01953328
- -64.2% vs -4.3% NCT01953328
- -20.2% vs 2.6% NCT01588496
- -43.5% vs -11.7% NCT01984424
- -45.8% vs -12.9% NCT01763905
- -43.1% vs -12.9% NCT01763905
- -45.3% vs -11.4% NCT01984424
- -45.9% vs -13.7% NCT01763905
- -46.0% vs -13.7% NCT01763905
Lp(a), % change
- Alirocumab
- -29.3% vs -3.7%−25.6 vs placeboNCT01507831
64 other results
- -28.2% vs -3.1% NCT01507831
- -21.3% vs 6.4% NCT01926782
- -19.3% vs 9.8% NCT01926782
- -28.9% vs -5.5% NCT01926782
- -19.6% vs 7% NCT01926782
- -23.5% vs -8.7% NCT01617655
- -20.5% vs -5.9% NCT01644175
- -23.2% vs -1.5% NCT01617655
- -19.7% vs 0% NCT01644175
- -25.2% vs -7.5% NCT01623115
- -15.5% vs 4.1% NCT02023879
- -31.7% vs 1.3% NCT02584504
- -49.6% vs 1.3% NCT02584504
- -5.7% vs 2.2% NCT02023879
- -30.3% vs -10% NCT01709500
- -21.8% vs 4.1% NCT02023879
- -19% vs -0.5% NCT02585778
- -21.2% vs -3.9% NCT01623115
- -24.7% vs -5.6% NCT01709500
- -6.1% vs -1.2% NCT02326220
- -19.6% vs 8.8% NCT03156621
- -19.6% vs 8.8% NCT03156621
- -18.1% vs -4% NCT02326220
- -14% vs 6.4% NCT01926782
- -16.9% vs 9.8% NCT01926782
- -23% vs -0.5% NCT02585778
- -35.9% vs -2.3% NCT02289963
- -39.5% vs 2.5% NCT02107898
- -26.9% vs -5.5% NCT01926782
- -12.4% vs 7% NCT01926782
- -16.5% vs 2.2% NCT02023879
- -33.6% vs -1.7% NCT02289963
- -41.9% vs -0.5% NCT02107898
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16% vs -2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16.0% vs -2.5% NCT03510884
- -27.8% vs -6.1% NCT01644188
- -22.1% vs 1.1% NCT01644188
- -30.3% vs 4.0% NCT02715726
- -30.1% vs 6.3% NCT02715726
- -16.7% vs -12.3% NCT01644474
- -17.2% vs -14.2% NCT01644474
- -25.9% vs -7.3% NCT01709513
- -21.7% vs -4.5% NCT01709513
- -27.9% vs -5.2% NCT01730053
- -22.7% vs -5.2% NCT01730053
- -23.6% vs -20.2% NCT01730040
- -30.8% vs -20.2% NCT01730040
- -20.7% vs 3.5% NCT01730053
- -16% vs 3.5% NCT01730053
- -24% vs -11.7% NCT01730040
- -27.9% vs -11.7% NCT01730040
- -24.7% vs -0.5% NCT02957682
- -22.4% vs -3.3% NCT02957682
- -24.3% vs -1.4% NCT02957682
- -25.1% vs -1.7% NCT02957682
- -17.7% vs 4.8% NCT02957682
- -23.7% vs 3.7% NCT02642159
- -55.8% vs -17.2% NCT02984982
- Evolocumab
- -16.4% vs 10.3%−26.8 vs placeboNCT02833844
52 other results
- -27.7% vs -5.4% NCT01516879
- -12.8% vs 1.1% NCT02729025
- -25.9% vs 11.4% NCT01763866
- -20.3% vs 11.4% NCT01763866
- -24.6% vs 11.4% NCT01763866
- -24.7% vs 11.4% NCT01763866
- -25.1% vs 11.4% NCT01763866
- -20.9% vs 11.4% NCT01763866
- -26.1% vs 11.4% NCT01763866
- -22.0% vs 11.4% NCT01763866
- -38.1% vs 11.4% NCT01763866
- -29.2% vs 11.4% NCT01763866
- -20.4% vs 0% NCT01763827
- -17.8% vs 0% NCT01763827
- -25.2% vs 7.4% NCT02739984
- -42.3% vs 16.9% NCT02662569
- -22.9% vs 6.7% NCT01763918
- -21.6% vs 6.7% NCT01763918
- -35.9% vs 26.5% NCT02662569
- -37.9% vs 26.5% NCT02662569
- -45.7% vs 10.8% NCT01953328
- -41.7% vs 10.8% NCT01953328
- -41.9% vs 10.8% NCT01953328
- -45.7% vs 10.8% NCT01953328
- -45.0% vs 6.5% NCT01953328
- -49.5% vs 6.5% NCT01953328
- -26.0% vs 11.4% NCT01763866
- -22.6% vs 11.4% NCT01763866
- -24.0% vs 11.4% NCT01763866
- -27.5% vs 11.4% NCT01763866
- -24.3% vs 11.4% NCT01763866
- -23.2% vs 11.4% NCT01763866
- -25.0% vs 11.4% NCT01763866
- -25.9% vs 11.4% NCT01763866
- -38.6% vs 11.4% NCT01763866
- -32.2% vs 11.4% NCT01763866
- -18.4% vs 0% NCT01763827
- -19.2% vs 0% NCT01763827
- -24.0% vs 5.3% NCT01763918
- -25.6% vs 5.3% NCT01763918
- -38.6% vs 16.9% NCT02662569
- -30.9% vs 9.6% NCT02739984
- -9.4% vs 2.4% NCT01588496
- -46.0% vs 6.5% NCT01953328
- -43.0% vs 6.5% NCT01953328
- -12.7% vs -1.4% NCT01588496
- -21.1% vs 0.2% NCT01984424
- -27.0% vs -1.7% NCT01763905
- -22.1% vs -1.7% NCT01763905
- -22.7% vs -1.6% NCT01984424
- -26.2% vs -2.3% NCT01763905
- -23.7% vs -2.3% NCT01763905
3-point MACE (% with event)
- Alirocumab
- —Not posted · NCT04790513
- Evolocumab
- 7.9% vs 9.9%−2 vs placeboNCT01764633
5 other results
- 6.7% vs 8.3% NCT01764633
- 5.5% vs 6.8% NCT01764633
- 4.3% vs 5.2% NCT01764633
- 3.1% vs 3.7% NCT01764633
- 1.6% vs 1.9% NCT01764633
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety
Coverage. Alirocumab: 24 of 24 rows · Evolocumab: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alirocumab Rows use multiple source trials | Evolocumab Rows use multiple source trials |
|---|---|---|
| All-cause Mortality responder rate · % of participants | 3.5% (n=9462) vs 4.1% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c NCT01663402 · Phase 3 | 4.75% (n=13784) vs 4.28% (n=13780) placebo @ 156wka,b,c NCT01764633 · Phase 3 |
| Apo B percent change · % of baseline No placebo or comparator arm | -43.1% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b NCT01954394 · Phase 3 · registry result, not featured evidence | -20.38% (n=106) @ 168wkd,a,b NCT01624142 · Phase 2/3 |
| CANTAB SWM Strategy absolute change · score | -1 vs -0.9 placebo score @ 96wk75 Q2W/Up150 Q2We,a,b,c NCT02957682 · Phase 4 · registry result, not featured evidence | 0.1134 vs 0.1206 placebo scoree,a,b,c NCT02207634 · Phase 3 |
| Coronary Revascularization responder rate · % of participants | 7.7% (n=9462) vs 8.8% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c NCT01663402 · Phase 3 | 7.01% (n=13784) vs 9.17% (n=13780) placebo @ 156wka,b,c NCT01764633 · Phase 3 |
| CV Death responder rate · % of participants | 2.5% (n=9462) vs 2.9% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c NCT01663402 · Phase 3 | 2.49% (n=13784) vs 2.39% (n=13780) placebo @ 156wka,b,c NCT01764633 · Phase 3 |
| HDL-C percent change · % of baseline | 4% (n=1530) vs -0.6% (n=780) placebo @ 24wk150 mg Q2Wa,b,c NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 27 other source trials3.5% (n=205) vs -3.8% (n=106) placebo @ 24wk75/150 mg Q2W NCT01644175 · Phase 3 8.8% (n=322) vs 0.8% (n=163) placebo @ 24wk75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 6% (n=166) vs -0.8% (n=81) placebo @ 24wk75 mg/up to 150 mg NCT01709500 · Phase 3 3.6% (n=308) vs -1.5% (n=156) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 2.5% (n=144) vs -5.3% (n=71) placebo @ 24wk300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 6% (n=76) vs -1.5% (n=156) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 -0.1% (n=37) vs -5.3% (n=71) placebo @ 24wk75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 8.6% (n=467) vs 0.5% (n=240) Ezetimibe @ 24wk75 /up to 150 mg Q2W NCT01644188 · Phase 3 6% (n=52) vs 1.6% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W NCT01644474 · Phase 3 5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W NCT03510884 · Phase 3 5.6% (n=49) vs -0.8% (n=25) placebo @ 24wkQ2W NCT03510884 · Phase 3 3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 3.4% (n=50) vs -0.8% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 9% (n=1058) vs 3.8% (n=1051) placebo @ 24wk75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 14.5% (n=273) vs 8.2% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 8.3% (n=403) vs 6.5% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 7.7% (n=58) vs -2.4% (n=57) placebo @ 24wk150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 7.4% (n=115) vs -2.4% (n=57) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 7.7% (n=126) vs 6.8% (n=122) Ezetimibe @ 24wk75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 11.2% (n=49) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 8.1% (n=287) vs 7.3% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 13.8% (n=97) vs 6.2% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence 7.9% (n=143) vs 2.1% (n=72) placebo @ 24wk75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 9.1% (n=48) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 7.2% (n=53) vs 1.7% (n=48) Rosuvastatin @ 24wk75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 4.8% (n=55) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 7.7% (n=46) vs 1.9% (n=53) Atorvastatin @ 24wk75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination | 5.54% (n=110) vs -0.99% (n=56) placeboQ2Wf,a,b,c NCT01763866 · Phase 3 show 9 more doses7.66% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 8.44% (n=109) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 7.76% (n=110) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 4.86% (n=111) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 6.35% (n=112) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 6.23% (n=113) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 7.72% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 10.35% (n=112) vs -0.99% (n=56) placeboQ2W NCT01763866 · Phase 3 6.71% (n=115) vs -0.99% (n=56) placeboQM NCT01763866 · Phase 3 |
| LDL-C absolute change · mg/dL | -62.4 vs -9.6 Standard of Care mg/dL @ 12wke,a,b NCT02984982 · Phase 4 · registry result, not featured evidence | -76.8 vs 6.8 placebo mg/dLQ2Wf,e,a,b NCT01763866 · Phase 3 show 19 more doses-77 vs 8.6 placebo mg/dL @ 12wkQ2W NCT01763866 · Phase 3 -80.1 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -75.1 vs 8.6 placebo mg/dL @ 12wkQM NCT01763866 · Phase 3 -58.8 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -59 vs 8.6 placebo mg/dL @ 12wkQ2W NCT01763866 · Phase 3 -60.1 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -54.8 vs 8.6 placebo mg/dL @ 12wkQM NCT01763866 · Phase 3 -52.3 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -52.1 vs 8.6 placebo mg/dL @ 12wkQ2W NCT01763866 · Phase 3 -55.3 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -46.7 vs 8.6 placebo mg/dL @ 12wkQM NCT01763866 · Phase 3 -68.9 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -69.2 vs 8.6 placebo mg/dL @ 12wkQ2W NCT01763866 · Phase 3 -77.8 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -73.3 vs 8.6 placebo mg/dL @ 12wkQM NCT01763866 · Phase 3 -83.8 vs 6.8 placebo mg/dLQ2W NCT01763866 · Phase 3 -83.5 vs 8.6 placebo mg/dL @ 12wkQ2W NCT01763866 · Phase 3 -78.4 vs 6.8 placebo mg/dLQM NCT01763866 · Phase 3 -72.5 vs 8.6 placebo mg/dL @ 12wkQM NCT01763866 · Phase 3 |
| LDL-C percent change · % of baseline No placebo or comparator arm | -52.2% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b NCT01954394 · Phase 3 · registry result, not featured evidence | -29.52% (n=106) @ 168wkd,a,b NCT01624142 · Phase 2/3 2 other source trials-64.5% (n=82) NCT01879319 · Phase 3 · registry result, not featured evidence -67.9% (n=82) NCT01879319 · Phase 3 · registry result, not featured evidence |
| LDL-C absolute change · mg/dL No placebo or comparator arm | -99.4 mg/dL @ 168wk75 or 150 mg Q2Wa,b,g NCT01954394 · Phase 3 · registry result, not featured evidence | -63.1 mg/dL @ 80wk420 mg QMf,a,b,g NCT02624869 · Phase 3 show 2 more doses-67.2 mg/dL @ 80wk420 mg QM NCT02624869 · Phase 3 -36.5 mg/dL @ 80wk420 mg QM NCT02624869 · Phase 3 |
| LDL-C percent change · % of baseline Extension (open-label) No placebo or comparator arm | -55.67% (n=42) @ 52wkh,a,b NCT01576484 · Phase 2 · registry result, not featured evidence | -51.3% (n=770) @ 52wkh,a,b NCT02304484 · Phase 3 · registry result, not featured evidence |
| LDL-C 15% Reduction responder rate · % of participants No placebo or comparator arm | 39% (n=18) @ 48wkd,i,b NCT03510715 · Phase 3 · registry result, not featured evidence | 60.2% (n=106) @ 48wkd,i,b NCT01624142 · Phase 2/3 |
| LDL-C 50 Reduction responder rate · % of participants | 43.9% (n=41) vs 0% (n=21) placebo @ 18wk150 mg Q2Wi,b,j NCT02326220 · Phase 3 | 72.5% (n=295) vs 0.7% (n=151) placebo @ 24wki,b,j NCT02833844 · Phase 3 · registry result, not featured evidence 1 other source trial84.2% (n=280) vs 0.7% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence |
| LDL-C Less Than 70 responder rate · % of participants | 79.3% (n=1530) vs 8% (n=780) placebo @ 24wk150 mg Q2Wf,a,b,c NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 1 more dose81.2% (n=1523) vs 8% (n=777) placebo @ 24wk150 mg Q2W NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 | 88.1% (n=110) vs 5.7% (n=56) placeboQ2Wf,a,b,c NCT01763866 · Phase 3 show 9 more doses85.8% (n=110) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 94.4% (n=109) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 92.5% (n=110) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 93.5% (n=111) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 94.5% (n=112) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 88.7% (n=113) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 89.9% (n=115) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 93.6% (n=112) vs 5.7% (n=56) placeboQ2W NCT01763866 · Phase 3 88.5% (n=115) vs 5.7% (n=56) placeboQM NCT01763866 · Phase 3 |
| Lp(a percent change · % of baseline No placebo or comparator arm | -29.2% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b NCT01954394 · Phase 3 · registry result, not featured evidence | -22.94% (n=106) @ 168wkd,a,b NCT01624142 · Phase 2/3 |
| MACE Composite responder rate · % of participants | 9.5% (n=9462) vs 11.1% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c NCT01663402 · Phase 3 | 12.57% (n=13784) vs 14.64% (n=13780) placebo @ 156wka,b,c NCT01764633 · Phase 3 |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | -47.7% (n=651) @ 168wk75 or 150 mg Q2Wd,a,b NCT01954394 · Phase 3 · registry result, not featured evidence | -27.97% (n=106) @ 168wkd,a,b NCT01624142 · Phase 2/3 |
| PAV absolute change · percentage points | -1.42% (n=93) vs -1.28% (n=89) Standard of Care @ 36wke,a,b,k NCT02984982 · Phase 4 · registry result, not featured evidence | -0.955% (n=423) vs 0.053% (n=423) placebo @ 78wke,a,b,k NCT01813422 · Phase 3 · registry result, not featured evidence |
| Stroke responder rate · % of participants | 1.2% (n=9462) vs 1.6% (n=9462) placebo75 mg Q2W/Up to 150 mg Q2Wa,b,c NCT01663402 · Phase 3 | 2.18% (n=13784) vs 2.6% (n=13780) placebo @ 156wkf,a,b,c NCT01764633 · Phase 3 show 1 more dose2.48% (n=13784) vs 2.81% (n=13780) placebo @ 156wk NCT01764633 · Phase 3 |
| Total Cholesterol percent change · % of baseline | -27.9% (n=205) vs -2.9% (n=106) placebo @ 24wk75/150 mg Q2Wi,b NCT01644175 · Phase 3 10 other source trials-29.6% (n=52) vs -10.9% (n=51) Ezetimibe @ 24wk75/Up to 150 mg Q2W NCT01644474 · Phase 3 -23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W NCT03510884 · Phase 3 -23.4% (n=49) vs 7.4% (n=25) placebo @ 24wkQ2W NCT03510884 · Phase 3 -27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 -27.7% (n=50) vs 7.4% (n=25) placebo @ 24wkQ4W NCT03510884 · Phase 3 -27.4% (n=273) vs -2.8% (n=136) Usual Care @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence -33.9% (n=403) vs -13.8% (n=208) Ezetimibe @ 24wk75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence -29.9% (n=49) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence -26.8% (n=287) vs -0.7% (n=25) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence -31.2% (n=97) vs 4% (n=102) placebo @ 24wk75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence | -35.78% (n=296) vs 2.34% (n=152) placebo @ 24wki,b NCT02833844 · Phase 3 · registry result, not featured evidence 5 other source trials-38.64% (n=325) vs 2.89% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -39.74% (n=332) vs 2.89% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -38.04% (n=145) vs -11.43% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -36.64% (n=145) vs -11.57% (n=73) Ezetimibe @ 24wk NCT01984424 · Phase 3 · registry result, not featured evidence -42.19% (n=280) vs -1.13% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence |
| Triglycerides percent change · % of baseline | -2.4% (n=41) vs 4.1% (n=21) placebo @ 18wk150 mg Q2Wa,b,l NCT02326220 · Phase 3 | -2.55% (n=599) vs 8.99% (n=302) placebo @ 52wka,b,l NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 20 other source trials-5.61% (n=110) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -13.38% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.27% (n=109) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -6.36% (n=110) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.15% (n=111) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -15.43% (n=112) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -10.28% (n=113) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -7.26% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -11.67% (n=112) vs 6.49% (n=56) placeboQ2W NCT01763866 · Phase 3 -15.93% (n=115) vs 6.49% (n=56) placeboQM NCT01763866 · Phase 3 -9.16% (n=153) vs -3.89% (n=76) placeboQ2W NCT01763827 · Phase 3 -15.71% (n=153) vs -3.89% (n=76) placeboQM NCT01763827 · Phase 3 -13.27% (n=110) vs 9.09% (n=54) placeboQ2W NCT01763918 · Phase 3 -9.25% (n=110) vs 9.09% (n=54) placeboQM NCT01763918 · Phase 3 -6.48% (n=325) vs 11.54% (n=164) placeboQ2W NCT02662569 · Phase 3 · registry result, not featured evidence -7.15% (n=332) vs 11.54% (n=164) placeboQM NCT02662569 · Phase 3 · registry result, not featured evidence -5.39% (n=145) vs -0.95% (n=73) Ezetimibe NCT01984424 · Phase 3 · registry result, not featured evidence -12.64% (n=280) vs 6.61% (n=141) placebo NCT02739984 · Phase 3 · registry result, not featured evidence -6.32% (n=103) vs -3.74% (n=51) EzetimibeQ2W NCT01763905 · Phase 3 · registry result, not featured evidence -6.73% (n=102) vs -3.74% (n=51) EzetimibeQM NCT01763905 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 28.3%150 mg Q2Wm NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results40.3%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 25.4%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 23.8%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 n/a: no completion milestone75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 12.8%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 28.1%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 16.7%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 21.6%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 25.5%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 15.4%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 0%150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 5.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.7%Q4W NCT03510884 · Phase 3 22%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 15.5%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 0% NCT02938949 · Phase 4 · registry result, not featured evidence 9.6% NCT02984982 · Phase 4 · registry result, not featured evidence 11.2%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 12% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence 5.7%New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 6.6%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 8.7%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 15.3%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 23.8%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9.6%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 10.3%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 8.3%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 22.4%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 24.1%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 19.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 19.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 41.3% NCT01576484 · Phase 2 · registry result, not featured evidence | 5.6%n NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results0%Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0.7% NCT01764633 · Phase 3 3.2% NCT02207634 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 7.3%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 5.4%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 10.5%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 1.7%QM NCT01763866 · Phase 3 3.9%Q2W NCT01763827 · Phase 3 1.3%QM NCT01763827 · Phase 3 9%Q2W NCT01763918 · Phase 3 1.8%QM NCT01763918 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 30.2% NCT01624142 · Phase 2/3 3%420 mg QM NCT02624869 · Phase 3 2%420 mg QM NCT02624869 · Phase 3 15.4%420 mg QM NCT02624869 · Phase 3 38.3% NCT04608474 · Phase 4 · registry result, not featured evidence 0%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 0%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence 14.5% NCT03689946 · Phase 3 · registry result, not featured evidence 16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 3.7% NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence 2.6%Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence 1.5%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 3.2% NCT02304484 · Phase 3 · registry result, not featured evidence 1.8%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 1.2%QM NCT02662569 · Phase 3 · registry result, not featured evidence 4.8% NCT01984424 · Phase 3 · registry result, not featured evidence 0.7% NCT02739984 · Phase 3 · registry result, not featured evidence 3.3% NCT01813422 · Phase 3 · registry result, not featured evidence 13%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 9.5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 8.7%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 6.1%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 2.4%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 5.4%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 1.3%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence 6.8%Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 7.3%150 mg Q2Wm NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results4.2%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 6.2%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 4%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 3%75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 5.4%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 9.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 5.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 8.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 4.9%150 mg Q2W NCT02326220 · Phase 3 9.2%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 9.6%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 0%Q4W NCT03510884 · Phase 3 3.8%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 6.2%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence — NCT02938949 · Phase 4 · registry result, not featured evidence 4.8% NCT02984982 · Phase 4 · registry result, not featured evidence 3.6%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 4.1% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 1.5%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 3.5%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 8.5%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 18.3%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 4.9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 2.1%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.9%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 6.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 3.7%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 8.8%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 4.3%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination —300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 2.2% NCT01576484 · Phase 2 · registry result, not featured evidence | —n NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 — NCT01764633 · Phase 3 — NCT02207634 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763866 · Phase 3 —QM NCT01763866 · Phase 3 —Q2W NCT01763827 · Phase 3 —QM NCT01763827 · Phase 3 —Q2W NCT01763918 · Phase 3 —QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 —420 mg QM NCT02392559 · Phase 3 — NCT01624142 · Phase 2/3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 —420 mg QM NCT02624869 · Phase 3 6.2% NCT04608474 · Phase 4 · registry result, not featured evidence —HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence —NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence — NCT03403374 · Phase 4 · registry result, not featured evidence — NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence —Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence — NCT03570697 · Phase 3 · registry result, not featured evidence — NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT02634580 · Phase 3 · registry result, not featured evidence —QM NCT02634580 · Phase 3 · registry result, not featured evidence —420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence — NCT02304484 · Phase 3 · registry result, not featured evidence —Q2W NCT02662569 · Phase 3 · registry result, not featured evidence —QM NCT02662569 · Phase 3 · registry result, not featured evidence — NCT01984424 · Phase 3 · registry result, not featured evidence — NCT02739984 · Phase 3 · registry result, not featured evidence — NCT01813422 · Phase 3 · registry result, not featured evidence —Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence —Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01953328 · Phase 3 · registry result, not featured evidence —QM NCT01953328 · Phase 3 · registry result, not featured evidence —Q2W NCT01763905 · Phase 3 · registry result, not featured evidence —QM NCT01763905 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence —Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence —Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence —All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence —All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination —SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 18.7%150 mg Q2Wm NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results—150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 13.9%150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 12.6%75 /up to 150 mg Q2W NCT01644175 · Phase 3 —75/150 mg Q2W NCT01644175 · Phase 3 13.7%75/Up to 150 mg Q2W NCT01623115 · Phase 3 —75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 6%75 mg/up to 150 mg NCT01709500 · Phase 3 11.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 11.3%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 3.4%150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —75 /up to 150 mg Q2W NCT01644188 · Phase 3 25.9%75/Up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644474 · Phase 3 1.9%75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 0%150 Q2W NCT03156621 · Phase 3 2.2%150 Q2W NCT03156621 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 8.7%Q2W NCT03510884 · Phase 3 6.1%Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 23.3%Alirocumab NCT01663402 · Phase 3 17.4%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 40% NCT02938949 · Phase 4 · registry result, not featured evidence 18.4% NCT02984982 · Phase 4 · registry result, not featured evidence 9.5%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 16.2% NCT02476006 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 10.1%75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 7.6%150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 22%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence 29.2%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 26.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 29.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 12.1%150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 6.1%75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 9.5%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 17.5%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence 7%75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence —75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 7.4%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 5.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 2.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 16.7%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 17.4% NCT01576484 · Phase 2 · registry result, not featured evidence | 5.5%n NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 64 more results—Part A: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 24.8% NCT01764633 · Phase 3 21.6% NCT02207634 · Phase 3 3.6%Q2W NCT01763866 · Phase 3 1.8%QM NCT01763866 · Phase 3 2.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 0.9%Q2W NCT01763866 · Phase 3 2.7%QM NCT01763866 · Phase 3 2.7%Q2W NCT01763866 · Phase 3 2.6%QM NCT01763866 · Phase 3 1.8%Q2W NCT01763866 · Phase 3 0.9%QM NCT01763866 · Phase 3 2%Q2W NCT01763827 · Phase 3 0.7%QM NCT01763827 · Phase 3 2.7%Q2W NCT01763918 · Phase 3 3.6%QM NCT01763918 · Phase 3 —420 mg QM NCT02392559 · Phase 3 1%420 mg QM NCT02392559 · Phase 3 27.4% NCT01624142 · Phase 2/3 2%420 mg QM NCT02624869 · Phase 3 4.1%420 mg QM NCT02624869 · Phase 3 16.7%420 mg QM NCT02624869 · Phase 3 0% NCT04608474 · Phase 4 · registry result, not featured evidence 5.3%HPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 4.5%NPR - Evolocumab NCT03096288 · Phase 4 · registry result, not featured evidence 6.7% NCT03403374 · Phase 4 · registry result, not featured evidence 0% NCT03689946 · Phase 3 · registry result, not featured evidence —Once Every 2 Weeks (Q2W) or Once a Month (QM) NCT02867813 · Phase 3 · registry result, not featured evidence 41.8%Evolocumab in Parent Study NCT02867813 · Phase 3 · registry result, not featured evidence 16.3% NCT03570697 · Phase 3 · registry result, not featured evidence 3.3% NCT02833844 · Phase 3 · registry result, not featured evidence —Evolocumab + Standard of Care NCT01854918 · Phase 3 · registry result, not featured evidence · combination 7.9%Year 1: Evolocumab + Standard of C NCT01854918 · Phase 3 · registry result, not featured evidence · combination 14.4%Years 2-3: Evolocumab + SOC / Evol NCT01854918 · Phase 3 · registry result, not featured evidence · combination 15.1%Years 2-3: SOC / Evolocumab + SOC NCT01854918 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT02634580 · Phase 3 · registry result, not featured evidence 0%QM NCT02634580 · Phase 3 · registry result, not featured evidence 3.1%420 mg QM NCT02729025 · Phase 3 · registry result, not featured evidence 19.9% NCT02304484 · Phase 3 · registry result, not featured evidence 3.1%Q2W NCT02662569 · Phase 3 · registry result, not featured evidence 6.6%QM NCT02662569 · Phase 3 · registry result, not featured evidence 6.2% NCT01984424 · Phase 3 · registry result, not featured evidence 5% NCT02739984 · Phase 3 · registry result, not featured evidence 27.9% NCT01813422 · Phase 3 · registry result, not featured evidence 0%Evolocumab NCT02189837 · Phase 3 · registry result, not featured evidence 5%Evolocumab and Atorvastatin NCT02189837 · Phase 3 · registry result, not featured evidence · combination 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 0%QM NCT01953328 · Phase 3 · registry result, not featured evidence 0%Q2W NCT01953328 · Phase 3 · registry result, not featured evidence 2%QM NCT01953328 · Phase 3 · registry result, not featured evidence 4.9%Q2W NCT01763905 · Phase 3 · registry result, not featured evidence 1%QM NCT01763905 · Phase 3 · registry result, not featured evidence 1.2%Evolocumab AI/Pen NCT01879319 · Phase 3 · registry result, not featured evidence 0%Evolocumab AMD NCT01879319 · Phase 3 · registry result, not featured evidence 2.7%Evolocumab AI/Pen NCT01849497 · Phase 3 · registry result, not featured evidence 4%Evolocumab PFS NCT01849497 · Phase 3 · registry result, not featured evidence 22%All-IP Period: Evolocumab + SOC / NCT01439880 · Phase 2 · registry result, not featured evidence 19.6%All-IP Period: SOC / Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence —Evolocumab + SOC NCT01439880 · Phase 2 · registry result, not featured evidence · combination 8.2%SOC-controlled Period: Evolocumab NCT01439880 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 150 mg Q2Wm nasopharyngitis 13.5% (placebo 13.1%) upper respiratory tract infection 7.4% (placebo 8.6%) injection site reaction 5.9% (placebo 4.2%) NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 60 more results150 Q2W nasopharyngitis 13.9% (placebo 11.4%) influenza 12.5% (placebo 2.9%) injection site reaction 8.3% (placebo 5.7%) NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 75 /up to 150 mg Q2W upper respiratory tract infection 7.7% (placebo 10.3%) nasopharyngitis 7.2% (placebo 4.7%) urinary tract infection 6.3% (placebo 3.7%) NCT01644175 · Phase 3 75/Up to 150 mg Q2W injection site reaction 12.4% (placebo 11%) nasopharyngitis 11.2% (placebo 7.4%) upper respiratory tract infection 6.8% (placebo 8.6%) NCT01623115 · Phase 3 75 mg/up to 150 mg influenza 14.4% (placebo 7.4%) injection site reaction 10.8% (placebo 7.4%) nasopharyngitis 10.8% (placebo 19.8%) NCT01709500 · Phase 3 300 mg Q4W/Up 150 mg Q2W injection site reaction 16.2% (placebo 7%) upper respiratory tract infection 9% (placebo 7.9%) nasopharyngitis 8.5% (placebo 7.9%) NCT01926782 · Phase 3 75 mg Q2W/Up 150 mg Q2W injection site reaction 8.7% (placebo 7%) nasopharyngitis 8.7% (placebo 7.9%) upper respiratory tract infection 7% (placebo 7.9%) NCT01926782 · Phase 3 150 mg Q2W fatigue 14.6% (placebo 9.5%) myalgia 12.2% (placebo 4.8%) diarrhoea 9.8% (placebo 0%) NCT02326220 · Phase 3 150 mg Q2W anaemia 6.9% (placebo 0%) nasopharyngitis 3.4% (placebo 9.5%) arthralgia 0% (placebo 9.5%) NCT02326220 · Phase 3 75/Up to 150 mg Q2W accidental overdose 9.8% upper respiratory tract infection 8.8% hypertension 6.5% NCT01644188 · Phase 3 150 Q2W diarrhoea 6.7% (placebo 0%) headache 4.4% (placebo 8.3%) nasopharyngitis 4.4% (placebo 0%) NCT03156621 · Phase 3 150 Q2W nasopharyngitis 6.7% (placebo 0%) diarrhoea 2.2% (placebo 0%) headache 2.2% (placebo 8.3%) NCT03156621 · Phase 3 Q2W nasopharyngitis 14.3% (placebo 8%) headache 6.1% (placebo 8%) injection site reaction 6.1% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 7.7% (placebo 8%) upper respiratory tract infection 5.8% (placebo 12%) injection site reaction 3.8% (placebo 0%) NCT03510884 · Phase 3 Q2W headache 10.9% (placebo 8%) oropharyngeal pain 8.7% (placebo 0%) injection site reaction 6.5% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 14.3% (placebo 8%) covid-19 8.2% (placebo 0%) nasopharyngitis 6.1% (placebo 8%) NCT03510884 · Phase 3 Q2W low density lipoprotein decreased 8% (placebo 0%) nasopharyngitis 8% (placebo 8%) nausea 8% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 16% (placebo 8%) covid-19 4% (placebo 0%) injection site reaction 4% (placebo 0%) NCT03510884 · Phase 3 nasopharyngitis 6% (placebo 5.6%) hypertension 5.7% (placebo 6.1%) myalgia 5.5% (placebo 5.3%) NCT01663402 · Phase 3 75 Q2W/Up150 Q2W nasopharyngitis 7.5% (placebo 8.2%) headache 6.5% (placebo 7.8%) hypertension 5.9% (placebo 6.7%) NCT02957682 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.2% injection site reaction 6.8% back pain 5.8% NCT02984982 · Phase 4 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W urinary tract infection 5.5% diarrhoea 5.1% arthralgia 2.2% NCT02642159 · Phase 4 · registry result, not featured evidence 150 mg Q2W nasopharyngitis 22.2% alanine aminotransferase increased 11.1% aortic valve incompetence 11.1% NCT03510715 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up to 150 mg Q2W aortic valve incompetence 22.2% headache 22.2% influenza 22.2% NCT03510715 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.8% myalgia 7.1% headache 6.1% NCT02476006 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.1% arthralgia 6.1% contusion 3% NCT03415178 · Phase 3 · registry result, not featured evidence urinary tract infection 6.1% arthralgia 4.5% contusion 1.5% NCT03415178 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up150 mg Q2W upper respiratory tract infection 13.3% accidental overdose 6.7% NCT02715726 · Phase 3 · registry result, not featured evidence 150 mg Q2W viral upper respiratory tract infection 15.1% (placebo 16.1%) non-cardiac chest pain 7.5% (placebo 1.8%) back pain 1.9% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 14.8% (placebo 16.1%) pharyngitis 5.6% (placebo 0%) back pain 0% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up Q2W viral upper respiratory tract infection 34.2% (placebo 16.1%) fall 7% (placebo 5.4%) back pain 5.1% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 75 or 150 mg Q2W viral upper respiratory tract infection 14.2% upper respiratory tract infection 10.8% influenza 9.3% NCT01954394 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 18.8% (placebo 5.2%) back pain 14.6% (placebo 0%) injection site reaction 14.6% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 15.1% (placebo 5.2%) fall 13.2% (placebo 1.7%) diarrhoea 10.4% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W cough 17.6% (placebo 0%) arthralgia 15.7% (placebo 6.9%) osteoarthritis 15.7% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up150 mg Q2W injection site reaction 13.8% (placebo 0%) arthralgia 12.1% (placebo 6.9%) headache 8.6% (placebo 6.9%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up150 mg Q2W headache 8.7% (placebo 6.9%) viral upper respiratory tract infection 8.7% (placebo 5.2%) muscle spasms 7.8% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg/ up to 150 mg myalgia 24.6% nasopharyngitis 6.3% upper respiratory tract infection 5.6% NCT01709513 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W nasopharyngitis 4.9% (placebo 5.3%) NCT02585778 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W dizziness 6.2% (placebo 2.9%) nasopharyngitis 6.2% (placebo 3.9%) diarrhoea 5.2% (placebo 1%) NCT02289963 · Phase 3 · registry result, not featured evidence 75 mg/ Up to 150 mg Q2W nasopharyngitis 45.5% (placebo 36.1%) back pain 12.6% (placebo 5.6%) injection site reaction 12.6% (placebo 4.2%) NCT02107898 · Phase 3 · registry result, not featured evidence 75 mg/up to 150 mg + 10 mg arthralgia 8.2% nausea 6.1% nasopharyngitis 4.1% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + 20 mg myalgia 7.4% upper respiratory tract infection 7.4% injection site reaction 5.6% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 20 mg muscle spasms 7% back pain 5.3% arthralgia 3.5% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 40 mg back pain 8.5% nasopharyngitis 8.5% accidental overdose 6.4% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 300 mg Q4W acne 20% diarrhoea 20% influenza like illness 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W nasopharyngitis 20% pyogenic granuloma 20% upper respiratory tract infection 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W abdominal discomfort 16.7% diarrhoea 16.7% epistaxis 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W ligament sprain 11.1% nasopharyngitis 11.1% abdominal pain 5.6% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W animal scratch 16.7% arthropod bite 16.7% blood follicle stimulating hormone decreased 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q4W abdominal pain 16.7% asthma 16.7% depressed mood 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 50 mg Q2W diarrhoea 33.3% nasopharyngitis 33.3% alcohol abuse 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W gastroenteritis viral 30% ear infection 10% headache 10% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W pharyngitis 25% abdominal discomfort 0% abdominal pain 0% NCT02890992 · Phase 2 · registry result, not featured evidence 30 mg Q2W ear infection 25% epistaxis 25% fall 25% NCT02890992 · Phase 2 · registry result, not featured evidence viral upper respiratory tract infection 40% acne 20% blood bilirubin increased 20% NCT01604824 · Phase 2 · registry result, not featured evidence gastroenteritis 33.3% viral upper respiratory tract infection 33.3% abdominal discomfort 16.7% NCT01604824 · Phase 2 · registry result, not featured evidence headache 28.6% acne 14.3% angina pectoris 14.3% NCT01604824 · Phase 2 · registry result, not featured evidence abdominal discomfort 20% abdominal distension 20% acne 20% NCT01604824 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 28.3% nasopharyngitis 23.9% bronchitis 21.7% NCT01576484 · Phase 2 · registry result, not featured evidence | n nasopharyngitis 10.5% (placebo 9.6%) upper respiratory tract infection 9.3% (placebo 6.3%) influenza 7.5% (placebo 6.3%) NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 54 more resultsbronchitis 12.5% (placebo 0%) dyspepsia 12.5% (placebo 0%) pain 12.5% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 influenza 9.1% (placebo 0%) upper respiratory tract infection 9.1% (placebo 6.3%) gastroenteritis 6.1% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 diabetes mellitus 8.4% (placebo 8%) hypertension 7.8% (placebo 8.4%) nasopharyngitis 7.7% (placebo 7.4%) NCT01764633 · Phase 3 nasopharyngitis 10.3% (placebo 7.5%) hypertension 6.2% (placebo 6.7%) back pain 5.9% (placebo 3.6%) NCT02207634 · Phase 3 Q2W muscle spasms 2.7% (placebo 0%) back pain 1.8% (placebo 0%) diarrhoea 1.8% (placebo 0%) NCT01763866 · Phase 3 QM muscle spasms 3.6% (placebo 0%) back pain 0.9% (placebo 0%) dizziness 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W diarrhoea 3.7% (placebo 0%) back pain 2.8% (placebo 0%) muscle spasms 1.8% (placebo 0%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) diarrhoea 1.8% (placebo 0%) myalgia 1.8% (placebo 3.6%) NCT01763866 · Phase 3 Q2W back pain 1.8% (placebo 0%) headache 1.8% (placebo 1.8%) myalgia 0.9% (placebo 3.6%) NCT01763866 · Phase 3 QM headache 2.7% (placebo 1.8%) back pain 0.9% (placebo 0%) diarrhoea 0.9% (placebo 0%) NCT01763866 · Phase 3 Q2W muscle spasms 1.8% (placebo 0%) back pain 0.9% (placebo 0%) constipation 0.9% (placebo 5.4%) NCT01763866 · Phase 3 QM back pain 1.7% (placebo 0%) diarrhoea 1.7% (placebo 0%) dizziness 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W back pain 5.4% (placebo 0%) dizziness 2.7% (placebo 0%) muscle spasms 2.7% (placebo 0%) NCT01763866 · Phase 3 QM headache 4.3% (placebo 1.8%) myalgia 2.6% (placebo 3.6%) back pain 1.7% (placebo 0%) NCT01763866 · Phase 3 Q2W headache 3.3% (placebo 3.9%) diarrhoea 2.6% (placebo 6.6%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 QM diarrhoea 3.3% (placebo 6.6%) headache 3.3% (placebo 3.9%) nasopharyngitis 2% (placebo 1.3%) NCT01763827 · Phase 3 Q2W nasopharyngitis 7.3% (placebo 3.7%) arthralgia 6.4% (placebo 1.9%) headache 3.6% (placebo 1.9%) NCT01763918 · Phase 3 QM nasopharyngitis 10% (placebo 3.7%) back pain 5.5% (placebo 0%) headache 4.5% (placebo 1.9%) NCT01763918 · Phase 3 420 mg QM nasopharyngitis 11.5% (placebo 11.3%) headache 10.6% (placebo 1.9%) oropharyngeal pain 6.7% (placebo 0%) NCT02392559 · Phase 3 allergic skin reaction 4.5% elevated creatine kinase 1.5% NCT04608474 · Phase 4 · registry result, not featured evidence angina pectoris 3.3% arthralgia 3.3% arthritis 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence runny nose 5.5% NCT03689946 · Phase 3 · registry result, not featured evidence hypertension 14.2% (placebo 12.9%) bronchitis 6.9% (placebo 6.4%) upper respiratory tract infection 6.5% (placebo 8.2%) NCT02867813 · Phase 3 · registry result, not featured evidence hypertension 7.5% (placebo 6.2%) myalgia 6.3% (placebo 7.4%) angina pectoris 5% (placebo 8.6%) NCT03570697 · Phase 3 · registry result, not featured evidence back pain 3.9% (placebo 2.5%) influenza like illness 3.9% (placebo 2.5%) diarrhoea 3.6% (placebo 4.5%) NCT02833844 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.2% arthralgia 4.3% upper respiratory tract infection 4.2% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.6% hypertension 7.5% upper respiratory tract infection 7.4% NCT01854918 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 12.6% upper respiratory tract infection 8.3% arthralgia 6.7% NCT01854918 · Phase 3 · registry result, not featured evidence · combination Q2W pharyngitis 15.8% abdominal distension 10.5% abdominal pain 5.3% NCT02634580 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 23.8% hypertension 9.5% injection site pain 9.5% NCT02634580 · Phase 3 · registry result, not featured evidence 420 mg QM influenza 10.8% (placebo 4.7%) nasopharyngitis 9.2% (placebo 20.3%) myalgia 7.7% (placebo 1.6%) NCT02729025 · Phase 3 · registry result, not featured evidence hypertension 6.4% NCT02304484 · Phase 3 · registry result, not featured evidence Q2W diabetes mellitus 4.6% (placebo 1.2%) nasopharyngitis 2.8% (placebo 3.7%) upper respiratory tract infection 2.8% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence QM diabetes mellitus 4.5% (placebo 1.2%) upper respiratory tract infection 3.9% (placebo 3.7%) nasopharyngitis 3.3% (placebo 3.7%) NCT02662569 · Phase 3 · registry result, not featured evidence myalgia 13.8% nasopharyngitis 9.7% arthralgia 9% NCT01984424 · Phase 3 · registry result, not featured evidence hypertension 3.9% (placebo 0%) diabetes mellitus 2.9% (placebo 3.5%) diarrhoea 2.1% (placebo 2.8%) NCT02739984 · Phase 3 · registry result, not featured evidence myalgia 7% (placebo 5.6%) chest pain 6.8% (placebo 5.4%) hypertension 6% (placebo 7%) NCT01813422 · Phase 3 · registry result, not featured evidence headache 36.4% (placebo 9.5%) influenza like illness 9.1% (placebo 0%) nasopharyngitis 9.1% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence headache 35% (placebo 9.5%) myalgia 10% (placebo 4.8%) nausea 10% (placebo 4.8%) NCT02189837 · Phase 3 · registry result, not featured evidence · combination Q2W nasopharyngitis 13.7% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 0% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 15.7% (placebo 9.6%) gastroenteritis 5.9% (placebo 1.9%) diabetes mellitus 3.9% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W nasopharyngitis 24% (placebo 9.6%) diabetes mellitus 2% (placebo 0%) gastroenteritis 2% (placebo 1.9%) NCT01953328 · Phase 3 · registry result, not featured evidence QM nasopharyngitis 14% (placebo 9.6%) gastroenteritis 4% (placebo 1.9%) diabetes mellitus 0% (placebo 0%) NCT01953328 · Phase 3 · registry result, not featured evidence Q2W myalgia 6.8% muscle spasms 4.9% nasopharyngitis 4.9% NCT01763905 · Phase 3 · registry result, not featured evidence QM headache 11.8% pain in extremity 11.8% myalgia 8.8% NCT01763905 · Phase 3 · registry result, not featured evidence headache 2.7% NCT01849497 · Phase 3 · registry result, not featured evidence headache 5.3% NCT01849497 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.7% upper respiratory tract infection 14.4% back pain 14.2% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 30.7% arthralgia 15.8% upper respiratory tract infection 14.3% NCT01439880 · Phase 2 · registry result, not featured evidence nasopharyngitis 16.8% upper respiratory tract infection 8.2% back pain 7% NCT01439880 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 2/3 versus Phase 3.
- eTrial phases differ: Phase 3 versus Phase 4.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gAssessment timepoints differ: 80 weeks versus 168 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iPopulation context differs: registered conditions differ.
- jAssessment timepoints differ: 24 weeks versus 18 weeks.
- kAssessment timepoints differ: 78 weeks versus 36 weeks.
- lAssessment timepoints differ: 52 weeks versus 18 weeks.
- mPopulation comparability has not been reviewed for 82 of these studies.
- nPopulation comparability has not been reviewed for 60 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alirocumab
show 36 more results
show 25 more results
show 1 more result
show 59 more results
show 53 more results
show 7 more results
show 1 more result
show 10 more results
show 8 more results
+ 69 further endpoints in the CSV export.
Evolocumab
show 47 more results
show 5 more results
show 5 more results
show 5 more results
show 46 more results
show 46 more results
show 25 more results
show 25 more results
+ 13 further endpoints in the CSV export.
Homozygous Familial Hypercholesterolemia
Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals and partners
NCT03156621 · Phase 3 · completed
The trial randomized 69 participants 2:1 to triple-blinded alirocumab or matching placebo, and its primary LDL-cholesterol endpoint was met, with a statistically significant difference favoring alirocumab (p<0.0001). The record does not report a power or sample-size calculation, so the study provides meaningful but limited evidence despite its strong randomized and blinded design.
Reported efficacy
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand): Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) (met)
Result source: NCT03156621
Evolocumab · Repatha
Marketed by Amgen
NCT01588496 · Phase 2/3 · completed
The randomized, quadruple-blind, placebo-controlled Part B (n=49) used a hard, regulator-accepted endpoint (LDL-C change from baseline) and the primary comparison was statistically significant and strongly favored evolocumab (LS mean difference -30.93%, 95% CI -43.86 to -18.00, p<0.001). Part A was an open-label single-arm pilot, but the grade is based on the randomized placebo-controlled Part B, which provides strong evidence for the drug.
Reported efficacy
Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12): Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 (met)
Result source: NCT01588496
Results for Homozygous Familial Hypercholesterolemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Alirocumab: 8 of 8 rows · Evolocumab: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alirocumab Rows use multiple source trials | Evolocumab |
|---|---|---|
| Apo B percent change · % of baseline | -22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2Wa,b,c,d NCT03156621 · Phase 3 show 1 more dose-22.5% (n=45) vs 7.2% (n=24) placebo @ 12wk150 mg SC Q2W NCT03156621 · Phase 3 | -19.17% (n=33) vs 3.97% (n=16) placebo @ 12wka,b,c,d NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 1 more dose-20.24% (n=33) vs 2.65% (n=16) placebo NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 |
| Apo B percent change · % of baseline No placebo or comparator arm | -4.2% (n=18) @ 12wkb,c,d NCT03510715 · Phase 3 · registry result, not featured evidence | -14.9% (n=8) @ 12wkb,c,d NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 1 other source trial-6% (n=29) @ 12wk NCT03403374 · Phase 4 · registry result, not featured evidence |
| Lp(a percent change · % of baseline | -19.6% (n=45) vs 8.8% (n=24) placebo @ 12wk150 mg SC Q2Wb,c,d NCT03156621 · Phase 3 | -9.4% (n=33) vs 2.43% (n=16) placebo @ 12wka,b,c,d NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 1 more dose-12.71% (n=33) vs -1.43% (n=16) placebo NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 |
| Non-HDL-C percent change · % of baseline No placebo or comparator arm | -3.9% (n=18) @ 12wkb,c,d NCT03510715 · Phase 3 · registry result, not featured evidence | -16.6% (n=8) @ 12wkb,c,d NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 |
| Dropout rate | 0%150 mg SC Q2We NCT03156621 · Phase 3 show 4 more results—150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | 0%Part A: Evolocumabf NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results—Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | —150 mg SC Q2We NCT03156621 · Phase 3 show 4 more results—150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | —Part A: Evolocumabf NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results—Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 — NCT03403374 · Phase 4 · registry result, not featured evidence |
| Serious AEs | —150 mg SC Q2We NCT03156621 · Phase 3 show 4 more results0%150 Q2W NCT03156621 · Phase 3 2.2%150 Q2W NCT03156621 · Phase 3 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence | —Part A: Evolocumabf NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 4 more results0%Part A: OL Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 0%Part B: DB Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 —Part B: Evolocumab NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 6.7% NCT03403374 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | 150 Q2We diarrhoea 6.7% (placebo 0%) headache 4.4% (placebo 8.3%) nasopharyngitis 4.4% (placebo 0%) NCT03156621 · Phase 3 show 3 more results150 Q2W nasopharyngitis 6.7% (placebo 0%) diarrhoea 2.2% (placebo 0%) headache 2.2% (placebo 8.3%) NCT03156621 · Phase 3 150 mg Q2W nasopharyngitis 22.2% alanine aminotransferase increased 11.1% aortic valve incompetence 11.1% NCT03510715 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up to 150 mg Q2W aortic valve incompetence 22.2% headache 22.2% influenza 22.2% NCT03510715 · Phase 3 · registry result, not featured evidence | f bronchitis 12.5% (placebo 0%) dyspepsia 12.5% (placebo 0%) pain 12.5% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 show 2 more resultsinfluenza 9.1% (placebo 0%) upper respiratory tract infection 9.1% (placebo 6.3%) gastroenteritis 6.1% (placebo 0%) NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3 angina pectoris 3.3% arthralgia 3.3% arthritis 3.3% NCT03403374 · Phase 4 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2/3 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alirocumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · Evolocumab's landscape